Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

As an organ recipient, columnist Sam Kirton honors donors and their families each year by decorating holiday trees in the ...

Until then, my family chooses to remain thankful for the available PF treatments and hopeful about the advancements that are sure to come. A diagnosis of PF will change your life, but life is for the ...

Columnist Samuel Kirton attended the Pulmonary Fibrosis Foundation's Summit 2025, where the group's five-year strategic plan was unveiled.

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...